Health News

New drug to treat pancreatic cancer shows promising results in clinical trial

 4 months ago       56 Views

A clinical trial testing a new drug in pancreatic cancer had promising initial results, report researchers from the University of Michigan Rogel Cancer Center.

A phase 1 clinical trial looked at AZD1775, an inhibitor designed to block an enzyme called Wee1, which plays a role in DNA damage repair. The trial builds on almost 20 years of research at U-M focused on improving the treatment of pancreatic cancer that is too advanced for surgery.

Radiation and the chemotherapy drug gemcitabine, which are standard treatment for pancreatic cancer, both work by causing damage to DNA. But pancreatic cancer has a way of repairing that damage, which limits how effective these therapies can be. Rogel Cancer Center laboratory researchers, led by Meredith Morgan, Ph.D., found AZD1775 prevents pancreatic cancer from protecting itself against the effects of radiation and gemcitabine, while leaving normal cells relatively unaffected.


Author: @DailyCupofYoga

Source: news-medical.net

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.